Page last updated: 2024-11-04

sulfasalazine and Carcinoma, Squamous Cell of Head and Neck

sulfasalazine has been researched along with Carcinoma, Squamous Cell of Head and Neck in 1 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Okazaki, S1
Umene, K1
Yamasaki, J1
Suina, K1
Otsuki, Y1
Yoshikawa, M1
Minami, Y1
Masuko, T1
Kawaguchi, S1
Nakayama, H1
Banno, K1
Aoki, D1
Saya, H1
Nagano, O1

Other Studies

1 other study available for sulfasalazine and Carcinoma, Squamous Cell of Head and Neck

ArticleYear
Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Cancer science, 2019, Volume: 110, Issue:11

    Topics: Amino Acid Transport System ASC; Amino Acid Transport System y+; Animals; Anti-Inflammatory Agents,

2019